Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (≤ 2.0 cm) in patients with hepatitis-induced liver cirrhosis

Acta Radiologica

Volumn 54, Issue 2, 2013, Pages 127-136

  Park, Min Jung ^a   Kim, Young Kon ^a   Lee, Mi Hee ^b   Lee, Jiyoung Hwang Won Jae ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Soonchunhyang University   (South Korea)

Author keywords

Contrast agents; Diffusion weighted imaging; Gd EOB DTPA; Hepatocellular carcinoma; Magnetic resonance imaging

Indexed keywords

INTERNET PROTOCOLS; MAGNETIC RESONANCE IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY;

CONTRAST AGENT; DIAGNOSTIC PARAMETER; DIFFUSION WEIGHTED IMAGING; GD-EOB-DTPA; HEPATOCELLULAR CARCINOMA; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING (MRI); MULTIDETECTOR ROW COMPUTED TOMOGRAPHY;

DIFFUSION;

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TUMOR; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBSERVER VARIATION; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; VIROLOGY; VIRUS HEPATITIS;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBSERVER VARIATION; SENSITIVITY AND SPECIFICITY;

MLCS; MLOWN;

EID: 84876698401     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1258/ar.2012.120262     Document Type: Article

References (31)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340: 745-50
2. Yuen MF, Cheng CC, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000;31: 330-5
3. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009;373: 614-6
4. Bruix J, Sherman A, American Association for the Study of Liver Disease. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: 1020-1
5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35: 421-30
6. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005;42: 27-34
7. Haradome H, Grazioli L, Tinti R, et al. Additional value of gadoxetic acid-DTPA-enhanced hepatobiliary phase MR imaging in the diagnosis of early-stage hepatocellular carcinoma: comparison with dynamic triple-phase multidetector CT imaging. J Magn Reson Imaging 2011;34: 69-78
8. Jung G, Breuer J, Poll LW, et al. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent GD-EOB-DTPA. Acta Radiol 2006;47: 15-23
9. Brismar TB, Dahlstrom N, Edsborg N, et al. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol 2009;50: 709-15
10. Park G, Kim YK, Kim CS, et al. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010; 83: 1010-6
11. Sun HY, Lee JM, Shin CI, et al. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (, 1/4 2 cm in Diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging. Invest Radiol 2010;45: 96-103
12. Kim YK, Kim CS, Han YM, et al. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol 2010;45: 740-6
13. Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255: 459-66
14. Kim YK, Kim CS, Han YM, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr. 2009;33: 844-50
15. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2009;192: 1675-81
16. Nasu K, Kuroki Y, Tsukamoto T, et al. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. Am J Roentgenol 2009;193: 438-44
17. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008;246: 812-22
18. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254: 47-66
19. Kim YK, Kim CS, Han YM, et al. Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? Clin Radiol 2011;66: 489-96
20. Takayama T, Makuuchi M, Hirohashi S, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336: 1150-3
21. Edmondson HA, Steiner PE. Primary carcinoma of liver: study of 100 cases among 48,900 necropsies. Cancer 1954;7: 462-503
22. Rao JN, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics 1992;48: 577-85
23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-74
24. Sangiovanni A, Manini MA, Iavarone M, et al. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59: 638-44
25. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mmor smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47: 97-104
26. Tamada T, Ito K, Sone T, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 2009;29: 636-40
27. Piana G, Trinquart L, Meskine N, et al. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011;55: 126-32
28. Matsui O. Imaging of multistep human hepatocarcinogenesis of CT during intra-arterial contrast injection. Intervirology 2004; 47: 271-6
29. Suh YJ, Kim MJ, Choi JY, et al. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Am J Roentgenol 2011;197:W44-52
30. Cigarroa RG, Lange RA, Williams RH, et al. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86: 649-52
31. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology. 2008; 249:891-9